Dec 16, 2015
Autologous Transfusion
www.anaesthesia.co.in [email protected]
Indications
• Patient request• Difficulty in finding suitable
blood• Availability/Economic
considerations• Complications relating to blood
transfusion
Complications of blood transfusion
• Infection Hepatitis B and C, HIV, CMV, vCJD• Immunological Early: anaphylaxis, acute lung
injury, alloimmunization, urticaria, acute haemolysis
Delayed: delayed haemolysis, immunosuppression
Complications of blood transfusion
• Metabolic Hyperkalaemia, hypocalcaemia,
acid–base disturbance, coagulopathy• Physical Hypothermia, microemboli, air
embolus, circulatory overload
Allogeneic blood-sparing strategies
Pharmacological• Preoperative - Erythropoietin - Ferrous sulphate, vitamin B12,
folate - Discontinue drugs that may impair haemostasis• Perioperative - Aprotinin - DDAVP - Tranexamic acid - Topical haemostatic agents
Erythropoietin
Daily s/c inj for at least 10 days before surgery.
Disadvantages of erythropoietin• Expensive• Labour intensive• Side effects - thrombosis / hypertension.• Unsuitable for emergency surgery.• Restricted to patients aged less than 70
yearsStudies support use cardiac/ orthopaedic
surgery
Optimization of haemostatic function
• Discontinue NSAIDs, anticoagulants• Haematology advice – cong.
coagulopathy• Haemophilia - factor VIII conc.• Liver-associated coagulopathy -
vitamin K• CRF - preoperative dialysis improves
platelet function
Pharmacological manipulation- Periop.
Evidence supporting use from studies in cardiac surgery• Aprotinin - non-specific protease inhibitor /inhibits plasmin-
reducing fibrinolysis - Reduces blood loss in cardiac surgery - May be associated with graft failure - Use in valve surgery is proven - Hypersensitivity reactions• Tranexamic acid - synthetic antifibrinolytic drug - Minimal side effects - Effective in cardiac surgery.• Desmopressin acetate (DDAVP) - analogue of vasopressin - Increases conc. of factor VIII/ von Willebrand factor - Indicated in haemophilia or vonWillebrand’s - No evidence to support use in patients without congenital bleeding disorders.
Allogeneic blood-sparing strategies
Non-pharmacological• Anaesthetic technique - Regional anaesthesia - Careful positioning - Controlled hypotension - Avoidance of
hypertension/hypothermia• Surgical technique - Planning of procedure - Minimally invasive choices - Dissecting instruments - Use of tourniquets
Surgical techniques
• Staging of complicated procedures or sequencing a procedure harvesting a vein by one member of a team whilst another member prepares the receiving site.
• Use of minimally invasive surgical techniques e.g. laparoscopic surgery or interventional radiology for embolization of aneurysms
• Dissecting instruments – spare blood vessels / provide haemostasis e.g monopolar diathermy knife, laser, harmonic scalpel
• Topical agents e.g thrombin-based sealants, fibrin-based sealants and calcium alginate
- Role in reducing allogeneic transfusion is unclear• Tourniquets - clearer surgical field / unlikely to
contribute to blood-sparing
Allogeneic blood-sparing strategies
• Transfusion protocols Autologous transfusion - Preoperative donation - Acute normovolaemic
haemodilution - Cell salvage
Preoperative autologous blood donation (PABD)
Criteria for autologous donors (American Association of
BloodBanks (AABB) Standards for Blood Banks andTransfusion Services) • Candidates for preoperative collection - stable
patients for surgery in which blood transfusion is likely such as orthopedic, vascular, cardiac, thoracic and radical prostatectomy
• Hb not less than 11 g/dL or Hct 33% • No age or weight limits• May donate 10.5 mL/kg• Donations may be scheduled more than once a
week, but the last should occur no less than 72 hours before surgery
• Autologous blood with positive viral markers commonly precluded
Contraindications
1. Evidence of infection and risk of bacteremia2. Scheduled surgery to correct aortic stenosis3. Unstable angina4. Active seizure disorder.5. Myocardial infarction or cerebrovascular accident within 6 months of donation6. Patients with significant cardiac or pulmonary
disease who have not yet been cleared for surgery by their treating physician
7. High-grade left main coronary artery disease8. Cyanotic heart disease9. Uncontrolled hypertension
Standards no longer permits allogeneic transfusion of unused autologous units ("crossover") because autologous donors are not volunteer donors
PABD
• Efficacy of PABD depends on the degree of patient's erythropoiesis
• Compensatory erythropoiesis suboptimal under "standard" conditions [expansion in RBC volume of 11% (with no oral iron supplementation) to 19% (with oral iron supplementation) ]
• Not sufficient to prevent anemia • PABD results in perioperative anemia
and an increased likelihood of any blood transfusion
PABD
• “Aggressive“ autologous blood phlebotomy (twice weekly for 3 weeks, beginning 25 to 35 days before surgery)
• endogenous erythropoietin levels increase with RBC volume expansion of 19% to 26%
• Exogenous erythropoietin therapy stimulates erythropoiesis (Expansion up to 50% RBC volume)
PABD
• Transfusion Trigger - Hb/Hct level at which autologous blood should be given - Trials indicate that even critical care patients can tolerate substantial anemia ( Hb ranges of 7 to 9 g/dL) with no apparent benefit from more aggressive transfusion
PABD
Disadvantages of PABD• Labour intensive-identification of suitable
patients, organizing appropriately timed blood donation, storing the blood
• Storage life of blood (5 weeks) limits number of units that can be donated / reduces flexibility in the postponement of surgery
• Not suitable for emergency surgery.• Clerical errors can occur at any stage of
the process• Not suitable for anaemic patients /
ischaemic heart disease
Acute normovolaemic haemodilution (ANH)
Principle
• Removal of whole blood from a patient, while restoring the circulating blood volume with an acellular fluid shortly before an anticipated significant surgical blood loss
• Blood collected in standard blood bags containing anticoagulant
• Stored at room temperature • Reinfused during surgery after major blood loss has
ceased, or sooner• Simultaneous inf. of crystalloid (3: 1 ) or colloid (1:1) • Blood reinfused in the reverse order of collection• Augmented hemodilution (replacement of ANH
collected in part by synthetic oxygen carriers)
• V = EBV . Hi – Hf / Hav
• Physiological consequences - Increased cardiac output - Decreased viscosity
Criteria for selection
• High likelihood of transfusion•Hb > 12•No significant ds.•Absence of severe hypertension•Absence of infection
ANH
Advantages of ANH• Reduction in the RBC mass lost for a given blood loss• Perceived lower relative cost compared with PABD or
allogeneic blood transfusion• Almost negligible potential for clerical error because
blood is kept in the operating theatre until transfusion• Infectious and immunological complications
associated with allogeneic blood are avoided• Platelet function and coagulation factors are
preserved• Theoretically improved tissue oxygen delivery due to
right shift of oxygen dissociation curve and reduced viscosity.
Acute normovolaemic haemodilution (ANH)
Disadvantages of ANH• Greater haemodynamic instability• Hypovolaemia is more likely• Potential complications of administration
of large volumes ofcrystalloid.• Useful only in healthy adults having
surgery with substantial anticipated blood loss, who have a high preoperative haemoglobin and who can tolerate low intraoperative haemoglobin
Intraoperative cell salvagePhysics of cell saver•Technique based on centrifugation, separating red blood cells (RBC) from the lighter components and fluids, including plasma, saline and buffy coat •System filled with 100-200 ml heparinized saline (“priming”)•Blood released at the wound site aspirated via a double-lumen suction catheter (80-100 mmHg)•Anticoagulated •stored in a reservoir with a filter• pumped into a rotating separation chamber •washed with 1000-1500 ml saline and concentrated
Intraoperative cell salvage
Optimising red cell return - Suction - Rinsing of sponges - Anticoagulant - Collection reservoir
Intraoperative cell salvage
Advantages of cell salvage• Suitable for elective and emergency surgery.• Reduced risk of administration of incorrect blood• Reduced use of allogeneic blood
Disadvantages of cell salvage• No preservation of clotting factors or platelets necessary.• Initial financial outlay to buy the machine and train staff
(but the cost of the disposables is less than the cost of one unit
of blood)• Use in malignancy is controversial• Blood salvaged from contaminated fields is unsuitable for
re-infusion.
Factor VIIa
• central role in initiating the process of coagulation
• Active after forming complex with tissue factor• Activates factors IX and X• Induction of thrombin burst on surface of
activated platelets• Formation of fibrin clots at the site of vascular
injury• Fibrin clots are stable / resistant to premature
lysis• The use of for treatment of intractable life-
threatening haemorrhage is
Recombinant factor VIIa (rFVIIa) • FDA-approved – - Hemophiliacs with factor VIII or IX inhibitors - Factor VII deficiency • Novel therapy for the treatment of acquired
coagulopathies - severe trauma - intractable bleeding after pelvic surgery - life-threatening post-partum haemorrhage - pulmonary haemorrhage - correction of coagulopathy in neurosurgical
patients - Jehovah's Witness after cardiac surgery• Other uses of rFVIIa - severe thrombocytopenia - platelet function disorders - impaired liver function
rFVIIa
• Bolus dose - 90–120 mg kg1• used with caution in
- patients with known hypercoagulability
- DIC or other states of generalized
activation of the hemostatic system
www.anaesthesia.co.in [email protected]